Thomas Schinecker - Roche Holding Chief Diagnostics
| ROG Stock | CHF 253.50 0.80 0.31% |
Insider
Thomas Schinecker is Chief Diagnostics of Roche Holding AG
| Age | 48 |
| Phone | 41 61 688 11 11 |
| Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Suni Harford | UBS Group AG | 61 | |
| Robert PharmD | Novartis AG | 55 | |
| Kian Koh | UBS Group AG | 63 | |
| Hermann Geiger | Swiss Re AG | 60 | |
| Peter Giger | Zurich Insurance Group | 59 | |
| Steffen Lang | Novartis AG | 56 | |
| MarieFrance Tschudin | Novartis AG | 52 | |
| Alison Martin | Zurich Insurance Group | 49 | |
| Michael Dargan | UBS Group AG | 46 | |
| George Quinn | Zurich Insurance Group | 57 | |
| Elena Logutenkova | Swiss Re AG | N/A | |
| Kristof Terryn | Zurich Insurance Group | 56 | |
| Sarah Youngwood | UBS Group AG | 49 | |
| Tulsi Naidu | Zurich Insurance Group | 50 | |
| Christian Mumenthaler | Swiss Re AG | 54 | |
| Karen Hale | Novartis AG | 55 | |
| Ericson Chan | Zurich Insurance Group | 57 | |
| Richard Saynor | Novartis AG | 56 | |
| Mark Senkevics | Swiss Re AG | N/A | |
| Magdi Batato | Nestl SA | 64 | |
| Robert Karofsky | UBS Group AG | 56 | |
Management Performance
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Claudia Bockstiegel, G Counsel | ||
| Barbara Schadler, Head Communications | ||
| Johannes MD, Head Devel | ||
| Bruno Eschli, Head Relations | ||
| Thomas Schinecker, Chief Diagnostics | ||
| Cristina Wilbur, Chief Officer | ||
| William Anderson, Chief Pharmaceuticals | ||
| Alan Hippe, Chief Officer | ||
| Severin Schwan, CEO Director | ||
| Pascale Schmidt, Chief Officer |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.45 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 270.78 B | |||
| Shares Outstanding | 693.89 M | |||
| Shares Owned By Institutions | 40.30 % | |||
| Price To Earning | 20.07 X | |||
| Price To Book | 9.63 X | |||
| Price To Sales | 3.73 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Roche Stock Analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.